Company news

Press releases

19 April 2017

Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market

19 April 2017, London - Verona Pharma plc (AIM: VRP) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, annou…

Read more

18 April 2017

Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Application

18 April 2017, London – Verona Pharma plc (AIM: VRP) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announced today th…

Read more

4 April 2017

Verona Pharma Files Registration Statement for Proposed Global Offering

4 April, 2017, London – Verona Pharma plc (AIM: VRP.L) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, annou…

Read more

4 April 2017

Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis

4 April 2017, London – Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announced today that the first patient has been enrolled and…

Read more

31 March 2017

Appointment of Commercial Director and dry powder formulation development

Richard Hennings brings more than a decade of strategic commercial biopharma leadership

Read more

22 March 2017

Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554

Establishes research and operational platform for clinical trials covering COPD and Cystic Fibrosis

Read more

20 March 2017

2016 Annual Report and Accounts and Notice of AGM

20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, is pleased to confirm th…

Read more

8 February 2017

Result of General Meeting Consolidation of Share Capital

8 February 2017, London – Verona Pharma plc (AIM: VRP), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces that all reso…

Read more

18 January 2017

Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017

Download the 'Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017' by clicking here or by visiting our download centre here.

Read more

18 January 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Download the 'Proposed new Articles for adoption at Meeting on 8 February 2017' by clicking here, or from our download centre here.

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Results, reports, presentations and circulars

Downloads

Date Title Statement Presentation Report Webcast
20 March 2017

2017 AGM Notice

Statement      
27 February 2017

Annual report 2016

    Report  
18 January 2017

Shareholder Circular for consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017

Statement      
18 January 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Statement      
Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us